The Bonitás Venture Capital Fund II. (Bonitás Kockázati Tőkealap II., KTA II.) Was established in July 2018, with a registered capital of HUF 12.15 billion, and continues to operate within the framework of the GINOP-8.1.3 / B-17 Intelligent Specialization Venture Capital Program, largely from European Union funds. Product name: Bonitás Venture Capital Fund II.
KTA II. can invest in the HUF 200-1,500 million range, with a headquarter in an EEA member state and a site in Hungary, except for the Central Hungary region. The fund’s term expires in 31 December 2029. Investment policy follows a generalist approach, i.e. there is no sectoral constraint.
Although KTA II. pays special attention to agro-innovation, also prioritizing advanced medical and instrumental therapies, early diagnosis, clinical methods, drug research and development, the development of innovative healthcare solutions, advanced vehicle and other mechanical technologies, clean and renewable energy; solutions within energy sectors, the development of advanced environmental technologies, research and development of locally produced and processed high value-added foods, and infocommunication technologies.
The focus of its investment activities is on SMEs, which are already operating in the market and have high growth prospects, and on the other hand, KTA II. has a strong interest in innovative projects in the product development/MVP phase, or in the process of entering the market, or in the midst of international expansion.
You can find a detailed description of the program by clicking on the link below